Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

5 treatments under study, led by Pharmacological Study

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Early Phase 1 (1)

Trial Status

Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (1)

Showing 1 of 1 trials
NCT02338037Early Phase 1CompletedPrimary

Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors

Showing all 1 trials

Research Network

Common Treatments

  • Pharmacological Study1
  • Therapeutic Conventional Surgery1
  • Biopsy1
  • Eribulin Mesylate1
  • Microdialysis1

Active Sponsors

  • City of Hope Medical Center1
  • Eisai Inc.1
  • National Cancer Institute (NCI)1

Top Investigators

Related Conditions

  • Primary Brain Tumor1

Activity Timeline